Active Ingredient: Azithromycin
View All Indications and Usage for Zithromax Zithromax is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.
Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including: patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure patients on drugs known to prolong the QT interval patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA quinidine, procainamide or Class III dofetilide, amiodarone, sotalol antiarrhythmic agents.
Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. Hypertoxin-producing strains of C.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.
Exacerbation of Myasthenia Gravis Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy. Use in Sexually Transmitted Infections Zithromax, single dose 1 g packet at the recommended dose, should not be relied upon to treat gonorrhea or syphilis.
All patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis.
Appropriate antibacterial therapy and follow-up tests for these diseases should be initiated if infection is confirmed.
Development of Drug-Resistant Bacteria Prescribing Zithromax in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
In clinical trials, most of the reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug.
Approximately 0. Serious adverse reactions included angioedema and cholestatic jaundice.
Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract. Gastrointestinal: Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice.
Genitourinary: Monilia, vaginitis, and nephritis. Nervous System: Dizziness, headache, vertigo, and somnolence.
General: Fatigue. Allergic: Rash, photosensitivity, and angioedema. Chronic therapy with 1200 mg weekly regimen The nature of adverse reactions seen with the 1200 mg weekly dosing regimen for the prevention of Mycobacterium avium infection in severely immunocompromised HIV-infected patients were similar to those seen with short-term dosing regimens.